Goal and Learning Outcomes

Upon completion of this activity, participants will be able to:

  • Discuss strategies for identifying appropriate patients for implementation of PARP inhibitors in advanced ovarian cancer
  • Review clinical data on the safety, efficacy, and tolerability of PARP inhibitors in the maintenance and disease recurrence setting following platinum-based chemotherapy
  • Identify adverse events related to PARP inhibitors and outline potential strategies for management

Faculty

Summer B. Dewdney, MD

Assistant Professor, Gynecologic Oncology
Division of Obstetrics & Gynecology
Rush University Medical Center

Bradley Monk, MD, FACOG, FACS

Medical Director, Gynecologic Oncology Research
Arizona Oncology, US Oncology Network
Professor, Gynecologic Oncology
Arizona College of Medicine – Phoenix

Disclosures of Conflicts of Interest

As a provider of continuing education, Rush University Medical Center asks everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.